Keep Us Human:
If We're Truly Smart, We'll Refuse to Foolishly Tamper with Our DNA
By Bill McKibben,
Los Angeles Times
| 04. 14. 2003
The 50th anniversary of the double helix has been greeted with
worldwide hoopla. It began in February, the month that James
Watson and Francis Crick actually made their discovery, and
will culminate this month with the golden anniversary of the
paper they published announcing the news to the world.
The celebration is appropriate; understanding of the gene is
rivaled only by understanding of the atom as the great scientific
achievement of the last century. But just as cracking the atom
raised the deepest ethical and practical dilemmas, so too does
cracking the gene. Our new knowledge of genetic manipulation
forces us to ask a question other generations couldn't have
imagined: Are we a good enough species?
Consider Watson, who has been the towering figure in genetics
research since that first paper -- the "commanding general"
of the DNA revolution, in the words of London's Guardian. He
has used his fame and influence to push for changing human beings
in the most radical ways. Human embryos should be manipulated,
he has said, to increase intelligence, to eliminate shyness,
even to make...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...